Utang jangka cendhak marang ekuitas CASI Pharmaceuticals (CASI)

The price chart for CASI Pharmaceuticals (CASI) serves as an indicator for a business that introduces advanced anti-tumor agents to the PRC, minimizing R&D costs through licensing. Yields and capital inflows here depend on government drug subsidies in China, which determine the level of the 0.00 metric. The company's growth is driven by a strategic alliance with Western biopharma partners for the joint promotion of therapies.

CASI - Rasio utang jangka cendhak marang ekuitas CASI Pharmaceuticals ing rentang 04.07.2022 - 14.03.2026

Rincian metrik keuangan lan pasar CASI Pharmaceuticals, Inc (CASI)

- kuotasi lan prakiraan analis:

Rega saham CASI Pharmaceuticals|CASI - Prakiraan konsensus analis

- rincian kapitalisasi pasar:

Nilai pasar CASI Pharmaceuticals Inc.|CASI - Nilai Bisnis

- data ekuitas miturut neraca:

Nilai Buku saben Saham CASI Pharmaceuticals|CASI - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku casipharmaceuticals.com|CASI - Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Utang marang Ekuitas CASI Pharmaceuticals|CASI - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas CASI Pharmaceuticals|CASI - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku CASI Pharmaceuticals Inc.|CASI - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan CASI Pharmaceuticals|Likuiditas cepet casipharmaceuticals.com

- statistik bathi lan rasio pasar:

CASI - Penghasilan resik perusahaan

Pambiji fundamental:CASI Pharmaceuticals, Inc.

Produk mawa merek casipharmaceuticals.com

The specifics of the CASI Pharmaceuticals (CASI) pharmaceutical business, characterized by costly research and regulatory pressure, make the current level of short-term debt to equity a critical liquidity marker. The short-term liabilities to equity ratio demonstrates the company's dependence on rapid refinancing; while reducing this ratio minimizes default risk, excessive conservatism in borrowing may slow the pace of commercializing new drugs.

Perusahaan pesaing